Coeptis Therapeutics Holdings, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Christopher Ryan Schadel, Chief Marketing Officer of Z Squared Inc., was granted 2,806 Restricted Stock Units (RSUs) as a supplemental award.
NASDAQ
BSG Series CM, LLC reports a pro rata distribution of all Z Squared Inc. common stock to its members, ceasing its reporting obligations.
NASDAQ
Adam Craig Sohn, a Director at Z Squared Inc., was granted 9,868 Restricted Stock Units (RSUs) on April 27, 2026, with a grant-date fair value of $150,000.
NASDAQ
Z Squared Inc. Chief Marketing Officer, Christopher Ryan Schadel, has been granted stock options and restricted stock units as part of his executive employment agreement.
NASDAQ
Z Squared Inc. reports the grant of a stock option to Co-Chief Executive Officer David Halabu for 500,000 shares.
NASDAQ
Z Squared Inc. reports that Director Bryan Eric Fuerst was granted 9,868 Restricted Stock Units (RSUs) on April 27, 2026, as part of his independent director compensation.
NASDAQ
Z Squared Inc. reports the grant of 9,868 Restricted Stock Units to Director Kenneth Lyle Cooper, vesting over 36 months.
NASDAQ
Z Squared Inc. Chief Financial Officer, Brian Cogley, has been granted stock options and restricted stock units as part of an amended employment agreement.
NASDAQ
Michelle Burke, Co-Chief Executive Officer and Director of Z Squared Inc., received a stock grant valued at $250,000 as part of an amended service agreement.
NASDAQ
Coeptis Therapeutics CFO Brian Cogley acquired 22,500 shares through option exercise and a restricted stock grant via an option exchange program.
NASDAQ
Coeptis Therapeutics Director Tara DeSilva increased her direct beneficial ownership of common stock through option exercise and a restricted stock grant.
NASDAQ
Coeptis Therapeutics Holdings VP of Compliance and Secretary, Christine Elise Sheehy, increased her direct beneficial ownership through option exercise and a restricted stock grant.
NASDAQ
Director Philippe Deschamps reports receiving a grant of 5,700 non-qualified stock options in Coeptis Therapeutics Holdings, Inc.
NASDAQ
Brian Cogley, CFO of Coeptis Therapeutics Holdings, Inc., was granted 10,000 non-qualified stock options on March 4, 2025, under the company's 2022 equity incentive plan.
NASDAQ
Daniel Alexander Yerace, VP of Operations at Coeptis Therapeutics Holdings, Inc., reports the acquisition of 5,000 non-qualified stock options on March 4, 2025.
NASDAQ
Christine Sheehy, VP of Compliance and Secretary at Coeptis Therapeutics Holdings, reports the acquisition of non-qualified stock options.
NASDAQ
Director Gene Salkind received a grant of 5,700 non-qualified stock options from Coeptis Therapeutics Holdings, Inc. on March 4, 2025.
NASDAQ
CEO David Mehalick received a grant of 28,875 non-qualified stock options on March 4, 2025, under the company's 2022 equity incentive plan.
NASDAQ
Director Tara DeSilva received a grant of 5,700 non-qualified stock options under the 2022 equity incentive plan.
NASDAQ
Director Christopher Cochran received a grant of 5,700 non-qualified stock options in Coeptis Therapeutics Holdings, Inc.
NASDAQ
Director Chris Calise receives a grant of 5,700 non-qualified stock options in Coeptis Therapeutics Holdings, Inc.